Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Key result
Prasugrel reduces post-PCI ischemic events vs clopidogrel in ACS but increases maintenance-phase major bleeding.
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Ultimately, deciding which drug is preferable will be a matter of individual clinical judgment. The FDA made sure that prasugrel's label clearly articulates the balance between efficacy and risk--a balance that physicians will need to assess carefully when choosing treatment for individual patients.”
TKTim KinnairdConsultant cardiologist, University College Cardiff
“This recommendation is very welcome as it offers clinicians a wider choice to protect acute coronary syndrome patients against atherothrombotic events when undergoing PCI. It is important that all suitable treatment options are available so the most appropriate clinical decision to manage patients can be made particularly for higher-risk patients with other co-morbidities, such as diabetes.”
“It would be superficial to regard this as an overall negative result. It's absolutely correct to say the primary end point didn't show a statistically significant difference between prasugrel and clopidogrel in those ACS patients managed medically, but there are several fascinating and potentially important observations.”
Implication
Randomized trial demonstrates reduced ischemic events with prasugrel in acute coronary syndromes, indicating sustained early and long-term protection.
Key Points
- To assess whether the antiplatelet benefits and bleeding risks of prasugrel compared with clopidogrel emerge early, persist late, or remain consistent across different phases after percutaneous coronary intervention.
- Landmark analysis of the randomized, double-blind TRITON-TIMI 38 trial evaluating 13,608 patients with acute coronary syndromes undergoing percutaneous coronary intervention.
- Patients received either prasugrel (60 mg loading dose, 10 mg daily maintenance) or clopidogrel (300 mg loading dose, 75 mg daily maintenance) for a median follow-up of 14.5 months.
- Clinical outcomes—including cardiovascular death, myocardial infarction, stroke, stent thrombosis, and TIMI major bleeding—were analyzed during early (days 0 to 3) and late (day 3 to study end) intervals.
- Prasugrel significantly reduced the primary composite ischemic endpoint both early during days 0 to 3 (4.7% vs 5.6%; HR 0.82, 95% CI 0.71–0.96; p=0.01) and late from day 3 onward (5.6% vs 6.9%; HR 0.80, 95% CI 0.70–0.93; p=0.003).
- Stent thrombosis was reduced by prasugrel during both the early interval (HR 0.35, 95% CI 0.21–0.58; p<0.0001) and the late maintenance period (HR 0.60, 95% CI 0.37–0.99; p=0.04).
- TIMI major non-CABG bleeding did not differ significantly in the first 3 days (HR 1.04, 95% CI 0.64–1.70; p=0.87), but increased significantly with prasugrel during the late phase (HR 1.39, 95% CI 1.02–1.89; p=0.037).
Study Design
Type
RCT
Randomization
Randomized
PICO
P
Population
Patients with acute coronary syndromes undergoing percutaneous coronary intervention.
I
Intervention / Comparator
Prasugrel vs Clopidogrel
O
Primary Outcome
Ischemic events (including myocardial infarction, stent thrombosis, and urgent target vessel revascularization)
Cite This Study
Antman et al. (2008) conducted an RCT in Acute Coronary Syndromes. Prasugrel vs. Clopidogrel was evaluated on Ischemic events (including myocardial infarction, stent thrombosis, and urgent target vessel revascularization). Prasugrel was superior to clopidogrel for reducing ischemic events both early and late after PCI in ACS patients, but increased major bleeding predominantly during the maintenance phase.